AGEs, RAGEs and s-RAGE; friend or foe for cancer

Seminars in Cancer Biology

Volumn 49, Issue , 2018, Pages 44-55

  Ahmad, Saheem ^a   Khan, Hamda ^a   Siddiqui, Zeba ^a   Khan, Mohd Yasir ^a   Rehman, Shahnawaz ^a   Shahab, Uzma ^b   Godovikova, Tatyana ^c   Silnikov, Vladimir ^c   Moinuddin, ^d  

^a INTEGRAL UNIVERSITY   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

^c INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^d ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Cancer; Glycation; RAGE; Signalling pathways; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN S 100; TRANSCRIPTION FACTOR; LIGAND; TUMOR MARKER;

AGING; CANCER GROWTH; CARCINOGENESIS; DIABETES MELLITUS; GLYCATION; HUMAN; INFLAMMATION; MALIGNANT NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; DNA DAMAGE; GLYCOSYLATION; METABOLISM;

ANIMALS; BIOMARKERS, TUMOR; CARCINOGENESIS; DNA DAMAGE; GLYCATION END PRODUCTS, ADVANCED; GLYCOSYLATION; HUMANS; INFLAMMATION; LIGANDS; OXIDATIVE STRESS; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SIGNAL TRANSDUCTION;

EID: 85023631822     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.07.001     Document Type: Review

References (161)

1. Poljsak, B., Suput, D., Milisav, I., Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid. Med. Cell. Longevity, 2013, 2013.
2. Shahab, U., Moinuddin Ahmad, S., Dixit, K., Abidi, A., Alam, K., Ali, A., Acquired immunogenicity of human DNA damaged by N-hydroxy-N-Acetyl-4-aminobiphenyl. IUBMB Life 64:4 (2012), 340–345.
3. Moinuddin Dixit, K., Ahmad, S., Shahab, U., Alam, K., Ali, A., Human DNA damage by the synergistic action of 4-Aminobiphenyl and nitric oxide: an immunochemical study. Environ. Toxicol. 29:5 (2014), 568–576.
4. Shahab, U., Ahmad, S., Dixit, K., Habib, S., Alam, K., Ali, A., Genotoxic effect of N-hydroxy-4-acetylaminobiphenyl on human DNA: implications in bladder cancer. PLoS One, 8(1), 2013, e53205.
5. Martin, D.N., Starks, A.M., Ambs, S., Biological determinants of health disparities in prostate cancer. Curr. Opin. Oncol. 25:3 (2013), 235–241.
6. 2+. Biochem. Biophys. Res. Commun. 407:3 (2011), 568–574.
7. Roberts, M.J., Wondrak, G.T., Laurean, D.C., Jacobson, M.K., Jacobson, E.L., DNA damage by carbonyl stress in human skin cells. Mutat. Res./Fundam. Mol. Mech. Mutagen. 522:1 (2003), 45–56.
8. Mustafa, I., Ahmad, S., Dixit, K., Ahmad, J., Ali, A., Glycated human DNA is a preferred antigen for anti-DNA antibodies in diabetic patients. Diabetes Res. Clin. Pract. 95:1 (2012), 98–104.
9. Akhter, F., Khan, M.S., Shahab, U., Ahmad, S., Bio-physical characterization of ribose induced glycation: a mechanistic study on DNA perturbations. Int. J. Biol. Macromol. 58 (2013), 206–210.
10. Ahmad, S., Siddiqui, Z., Protein glycation: a firm link to cause metabolic disease and their complications. J. Glycomics Lipidomics, 5(1), 2015, 1.
11. Chan, J.S., Tan, M.J., Sng, M.K., Teo, Z., Phua, T., Choo, C.C., Liang, L.I., Zhu, P., Tan, N.S., Cancer-associated fibroblasts enact field cancerization by promoting extratumoral oxidative stress. Cell Death Dis., 8(1), 2017, e2562.
12. Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H.Z., Kamarul, T., Potential of apoptotic pathway-targeted cancer therapeutic research: where do we stand?. Cell Death Dis., 7(1), 2016, e2058.
13. Over 17 lakh new cancer cases in India by 2020: ICMR News (icmr.nic.in/icmrsq1/archive/2-16-17.pdf).
14. Ahmad, S., Khan, M.S., Akhter, F., Khan, M.S., Khan, A., Ashraf, J.M., Pandey, R.P., Shahab, U., Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation. Glycobiology, 2014, cwu057.
15. Vlassara, H., Striker, G.E., AGE restriction in diabetes mellitus: a paradigm shift. Nat. Rev. Endocrinol. 7:9 (2011), 526–539.
16. Guimaraes, M.D., Bitencourt, A.G., Marchiori, E., Chojniak, R., Gross, J.L., Kundra, V., Imaging acute complications in cancer patients: what should be evaluated in the emergency setting?. Cancer Imaging, 14(1), 2014, 18.
17. Ott, C., Jacobs, K., Haucke, E., Santos, A.N., Grune, T., Simm, A., Role of advanced glycation end products in cellular signaling. Redox Biol. 2 (2014), 411–429.
18. Meng, H.Z., Zhang, W.L., Liu, F., Yang, M.W., Advanced glycation end products affect osteoblast proliferation and function by modulating autophagy via the receptor of advanced glycation end products/Raf protein/mitogen-activated protein kinase/extracellular signal-regulated kinase/extracellular signal-regulated kinase (RAGE/Raf/MEK/ERK) pathway. J. Biol. Chem. 290:47 (2015), 28189–28199.
19. Goldin, A., Beckman, J.A., Schmidt, A.M., Creager, M.A., Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 114, 2006.
20. Yang, S., Pinney, S.M., Mallick, P., Ho, S.M., Bracken, B., Wu, T., Impact of oxidative stress biomarkers and carboxymethyllysine (an advanced glycation end product) on prostate cancer: a prospective study. Clin. Genitourin. Cancer 13:5 (2015), e347–51.
21. Sato, K., Yagi, M., Takabe, W., Yonei, Y., Inhibitory effect of plant extract on tumor necrosis factor-α formation from carboxymethyl-lysine stimulated macrophages. Glycative Stress Res., 2015, 191–196.
22. Hsia, T.C., Yin, M.C., Mong, M.C., Advanced glycation end-products enhance lung cancer cell invasion and migration. Int. J. Mol. Sci., 17(8), 2016, 1289.
23. Gönenç, A., Özkan, Y., Torun, M., Şimşek, B., Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J. Clin. Pharm. Ther. 26:2 (2001), 141–144.
24. Negritto, C., Repairing double-strand DNA breaks. Nat. Educ., 3(9), 2010, 26.
25. Ashraf, J.M., Shahab, U., Tabrez, S., Lee, E.J., Choi, I., Yusuf, M.A., Ahmad, S., DNA glycation from 3-deoxyglucosone leads to the formation of AGEs: potential role in cancer auto-antibodies. Cell Biochem. Biophys. 74:1 (2016), 67–77.
26. Dutta, U., Cohenford, M.A., Dain, J.A., Nonenzymatic glycation of DNA nucleosides with reducing sugars. Anal. Biochem. 345:2 (2005), 171–180.
27. Li, Y., Dutta, U., Cohenford, M.A., Dain, J.A., Nonenzymatic glycation of guanosine 5'-triphosphate by glyceraldehyde: an in vitro study of AGE formation. Bioorg. Chem. 35:6 (2007), 417–429.
28. Li, Y., Study on the Nonenzymatic Glycation of Nucleosides/nucleotides and Proteins with Sugars: An in Vitro Investigation of Advanced Glycation Endproducts (AGEs) Formation. 2008, University of Rhode Island.
29. Rabbani, N., Thornalley, P.J., Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem. Soc. Trans. 36 (2008), 1045–1050.
30. Li, Y., Cohenford, M.A., Dutta, U., Dain, J.A., The structural modification of DNA nucleosides by nonenzymatic glycation: an in vitro study based on the reactions of glyoxal and methylglyoxal with 2′-deoxyguanosine. Anal. Bioanal. Chem. 390:2 (2008), 679–688.
31. Akhter, F., Khan, M.S., Ahmad, S., Acquired immunogenicity of calf thymus DNA and LDL modified by D-ribose: a comparative study. Int. J. Biol. Macromol. 72 (2015), 1222–1227.
32. Ahmad, S., Akhter, F., Shahab, U., Khan, M.S., Studies on glycation of human low density lipoprotein: a functional insight into physico-chemical analysis. Int. J. Biol. Macromol. 62 (2013), 167–171.
33. Li, J., Liu, D., Sun, L., Lu, Y., Zhang, Z., Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci. 317:1 (2012), 1–5.
34. Ahmad, S., Shahab, U., Habib, S., Khan, M.S., Alam, K., Ali, A., Glycoxidative damage to human DNA: Neo-antigenic epitopes on DNA molecule could be a possible reason for autoimmune response in type 1 diabetes. Glycobiology 24:3 (2014), 281–291.
35. Ahmad, S., Uddin, M., Habib, S., Shahab, U., Alam, K., Ali, A., Autoimmune response to AGE modified human DNA: Implications in type 1 Diabetes mellitus. J. Clin. Transl. Endocrinol. 1:3 (2014), 66–72.
36. Shahab, U., Tabrez, S., Khan, M.S., Akhter, F., Khan, M.S., Saeed, M., Ahmad, K., Srivastava, A.K., Ahmad, S., Immunogenicity of DNA-advanced glycation end product fashioned through glyoxal and arginine in the presence of Fe 3+: Its potential role in prompt recognition of diabetes mellitus auto-antibodies. Chem. Biol. Interact. 219 (2014), 229–240.
37. Ahmad, M.I., Ahmad, Saheem, Moinuddin Preferential recognition of methylglyoxal modified calf thymus DNA by circulating auto-antibodies in cancer patients. Indian J. Biochem. Biophys. 48 (2011), 290–296.
38. Faisal, M., Shahab, U., Alatar, A.A., Ahmad, S., Preferential recognition of auto‐antibodies against 4‐hydroxynonenal modified DNA in the cancer patients. J. Clin. Lab. Anal.(Jan), 2017 (1).
39. Gumy-Pause, F., Wacker, P., Sappino, A.P., ATM gene and lymphoid malignancies. Leukemia 18:2 (2004), 238–242.
40. Pause, F.G., Wacker, P., Maillet, P., Betts, D., Sappino, A.P., ATM gene alterations in childhood acute lymphoblastic leukemias. Hum. Mutat., 21(5), 2003, 554.
41. Matsuoka, S., Ballif, B.A., Smogorzewska, A., McDonald, E.R., Hurov, K.E., Luo, J., Bakalarski, C.E., Zhao, Z., Solimini, N., Lerenthal, Y., Shiloh, Y., ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:5828 (2007), 1160–1166.
42. Durocher, D., Jackson, S.P., DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?. Curr. Opin. Cell Biol. 13:2 (2001), 225–231.
43. Selvaraj, N., Bobby, Z., Sathiyapriya, V., Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. Clin. Chim. Acta 366:1 (2006), 190–195.
44. Marnett, L.J., Lipid peroxidation—DNA damage by malondialdehyde. Mutat. Res./Fundam. Mol. Mech. Mutagen. 424:1 (1999), 83–95.
45. Mallick, A.K., Maradi, R., Joshi, V.R., Shorey, G., Ahsan, M., Study on malondialdehyde as a marker of lipid peroxidation in male and female patients with type 2 diabetes mellitus. Int. J. Pharm. Sci. Rev. Res. 8:2 (2011), 198–201.
46. Meenakshi, T., Dinesh, J., Adenosine Deami-nase and Malondialdehyde Levels in Type-2 Diabetes Mellitus −a Short Study, vol. 14, 2014.
47. Boyer, F., Diotel, N., Girard, D., Rondeau, P., Essop, M.F., Bourdon, E., Enhanced oxidative stress in adipose tissue from diabetic mice, possible contribution of glycated albumin. Biochem. Biophys. Res. Commun. 473:1 (2016), 154–160.
48. Hanash, S.M., Pitteri, S.J., Faca, V.M., Mining the plasma proteome for cancer biomarkers. Nature 452:7187 (2008), 571–579.
49. Ahmed, N., Thornalley, P.J., Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ann. N. Y. Acad. Sci. 1043:1 (2005), 260–266.
50. Koenig, R.J., Peterson, C.M., Jones, R.L., Saudek, C., Lehrman, M., Cerami, A., Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. New Engl. J. Med. 295:8 (1976), 417–420.
51. Koenig, R.J., Peterson, C.M., Kilo, C., Cerami, A., Williamson, J.R., Hemoglobin AIc as an indicator of the degree of glucose intolerance in diabetes. Diabetes 25:3 (1976), 230–232.
52. Koenig, R.J., Blobstein, S.H., Cerami, A.N., Structure of carbohydrate of hemoglobin AIc. J. Biol. Chem. 252:9 (1977), 2992–2997.
53. Khaw, K.T., Wareham, N., Bingham, S., Luben, R., Welch, A., Day, N., Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer–Norfolk study. Cancer Epidemiol. Prev. Biomarkers 13:6 (2004), 915–919.
54. Lin, J., Ridker, P.M., Rifai, N., Lee, I.M., Manson, J.E., Buring, J.E., Zhang, S.M., A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. Cancer Res. 66:5 (2006), 2869–2875.
55. Hardie, D.G., AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62:7 (2013), 2164–2172.
56. Sciacca, L., Vigneri, R., Tumminia, A., Frasca, F., Squatrito, S., Frittitta, L., Vigneri, P., Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr. Metab. Cardiovasc. Dis. 23:9 (2013), 808–815.
57. Shikata, K., Ninomiya, T., Kiyohara, Y., Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 104:1 (2013), 9–14.
58. Ott, C., Jacobs, K., Haucke, E., Santos, A.N., Grune, T., Simm, A., Role of advanced glycation end products in cellular signaling. Redox Biol. 2 (2014), 411–429.
59. Xie, J., Méndez, J.D., Méndez-Valenzuela, V., Aguilar-Hernández, M.M., Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell. Signal. 25:11 (2013), 2185–2197.
60. You, J., Peng, W., Lin, X., Huang, Q.L., Lin, J.Y., PLC/CAMK IV–NF-κB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells. Mol. Cell. Endocrinol. 320:1 (2010), 111–117.
61. Chen, H., Wu, L., Li, Y., Meng, J., Lin, N., Yang, D., Zhu, Y., Li, X., Li, M., Xu, Y., Wu, Y., Advanced glycation end products increase carbohydrate responsive element binding protein expression and promote cancer cell proliferation. Mol. Cell. Endocrinol. 395:1 (2014), 69–78.
62. Dutta, U., Cohenford, M.A., Dain, J.A., Nonenzymatic glycation of DNA nucleosides with reducing sugars. Anal. Biochem. 345:2 (2005), 171–180.
63. Uribarri, J., Woodruff, S., Goodman, S., Cai, W., Chen, X., Pyzik, R., Yong, A., Striker, G.E., Vlassara, H., Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet. Assoc. 110:6 (2010), 911–916.
64. Cerami, C., Founds, H., Nicholl, I., Mitsuhashi, T., Giordano, D., Vanpatten, S., Lee, A., Al-Abed, Y., Vlassara, H., Bucala, R., Cerami, A., Tobacco smoke is a source of toxic reactive glycation products. Proc. Natl. Acad. Sci. 94:25 (1997), 13915–13920.
65. Uribarri, J., Cai, W., Peppa, M., Goodman, S., Ferrucci, L., Striker, G., Vlassara, H., Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J. Gerontol. Series A: Biol. Sci. Med. Sci. 62:4 (2007), 427–433.
66. Ramasamy, R., Vannucci, S.J., DuYan, S.S., Herold, K., Yan, S.F., Schmidt, A.M., Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15:7 (2005), 16R–28R.
67. Sessa, L., Gatti, E., Zeni, F., Antonelli, A., Catucci, A., Koch, M., Pompilio, G., Fritz, G., Raucci, A., Bianchi, M.E., The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS One, 9(1), 2014, e86903.
68. Ott, C., Jacobs, K., Haucke, E., Santos, A.N., Grune, T., Simm, A., Role of advanced glycation end products in cellular signaling. Redox Biol. 2 (2014), 411–429.
69. Koch, M., Chitayat, S., Dattilo, B.M., Schiefner, A., Diez, J., Chazin, W.J., Fritz, G., Structural basis for ligand recognition and activation of RAGE. Structure 18:10 (2010), 1342–1352.
70. Fritz, G., RAGE: a single receptor fits multiple ligands. Trends Biochem. Sci. 36:12 (2011), 625–632.
71. Leung, S.S., Forbes, J.M., Borg, D.J., Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis. Curr. Diab. Rep., 16(10), 2016, 100.
72. Chen, Q., Guan, X., Zuo, X., Wang, J., Yin, W., The role of high mobility group Box 1 Box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharm. Sin. B 6:3 (2016), 183–188.
73. Shen, X., Li, W.Q., High-mobility group Box 1 Box 1 protein and its role in severe acute pancreatitis. World J. Gastroenterol.: WJG, 21(5), 2015, 1424.
74. Banerjee, S., de Freitas, A., Friggeri, A., Zmijewski, J.W., Liu, G., Abraham, E., Intracellular HMGB1 negatively regulates efferocytosis. J. Immunol. 187:9 (2011), 4686–4694.
75. Huttunen, H.J., Fages, C., Kuja-Panula, J., Ridley, A.J., Rauvala, H., Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62:16 (2002), 4805–4811.
76. Kang, R., Tang, D., Schapiro, N.E., Loux, T., Livesey, K.M., Billiar, T.R., Wang, H., Van Houten, B., Lotze, M.T., Zeh, H.J., The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 33:5 (2014), 567–577.
77. Andersson, U., Tracey, K.J., HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29 (2011), 139–162.
78. Gnanasekar, M., Kalyanasundaram, R., Zheng, G., Chen, A., Bosland, M.C., Kajdacsy-Balla, A., HMGB1: a promising therapeutic target for prostate cancer. Prostate Cancer, 2013, 2013.
79. Leclerc, E., Vetter, S.W., The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 1852:12 (2015), 2706–2711.
80. Ali, A., Brown, V., Denley, S., Jamieson, N.B., Morton, J.P., Nixon, C., Graham, J.S., Sansom, O.J., Carter, C.R., McKay, C.J., Duthie, F.R., Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clin. Pathol., 14(1), 2014, 35.
81. Hu, H., Zhang, Q., Huang, C., Shen, Y., Chen, X., Shi, X., Tang, W., Diagnostic value of S100P for pancreatic cancer: a meta-analysis. Tumor Biol. 35:10 (2014), 9479–9485.
82. Arumugam, T., Logsdon, C.D., S100P: a novel therapeutic target for cancer. Amino Acids 41:4 (2011), 893–899.
83. Arumugam, T., Ramachandran, V., Gomez, S.B., Schmidt, A.M., Logsdon, C.D., S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin. Cancer Res. 18:16 (2012), 4356–4364.
84. Tesarova, P., Kalousova, M., Zima, T., Tesar, V., HMGB1, S100 proteins and other RAGE ligands in cancer-markers, mediators and putative therapeutic targets. Biomed. Pap., 160(1), 2016 (1-0).
85. Liliensiek, B., Weigand, M.A., Bierhaus, A., Nicklas, W., Kasper, M., Hofer, S., Plachky, J., Gröne, H.J., Kurschus, F.C., Schmidt, A.M., Du Yan S: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113:11 (2004), 1641–1650.
86. Pullerits, R., Brisslert, M., Jonsson, I.M., Tarkowski, A., Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via β2 integrin Mac-1. Arthritis Rheumatol. 54:12 (2006), 3898–3907.
87. Sparvero, L.J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A.A., Zeh, H.J., Lotze, M.T., RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med., 7(1), 2009, 17.
88. Sasaki, N., Takeuchi, M., Chowei, H., Kikuchi, S., Hayashi, Y., Nakano, N., Ikeda, H., Yamagishi, S.I., Kitamoto, T., Saito, T., Makita, Z., Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett. 326:2 (2002), 117–120.
89. Schmidt, A.M., Du Yan S, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 1498:2 (2000), 99–111.
90. Chaney, M.O., Stine, W.B., Kokjohn, T.A., Kuo, Y.M., Esh, C., Rahman, A., Luehrs, D.C., Schmidt, A.M., Stern, D., Du Yan S, Roher AE: RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 1741:1 (2005), 199–205.
91. Li, Y., Wu, R., Tian, Y., Yu, M., Tang, Y., Cheng, H., Tian, Z., RAGE/NF-κB signaling mediates lipopolysaccharide induced acute lung injury in neonate rat model. Int. J. Clin. Exp. Med., 8(8), 2015, 13371.
92. Riehl, A., Németh, J., Angel, P., Hess, J., The receptor RAGE: Bridging inflammation and cancer. Cell Commun. Signaling, 7(1), 2009, 12.
93. Sever, R., Brugge, J.S., Signal transduction in cancer. Cold Spring Harbor Perspect. Med., 5(4), 2015, a006098.
94. Cichowski, K., Jacks, T., NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:4 (2001), 593–604.
95. Collak, F.K., Yagiz, K., Luthringer, D.J., Erkaya, B., Cinar, B., Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. J. Biol. Chem. 287:28 (2012), 23698–23709.
96. Diehl, J.A., Zindy, F., Sherr, C.J., Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11:8 (1997), 957–972.
97. Lin, L., Deng, W., Tian, Y., Chen, W., Wang, J., Fu, L., Shi, D., Zhao, M., Luo, W., Lasiodin inhibits proliferation of human nasopharyngeal carcinoma cells by simultaneous modulation of the Apaf-1/Caspase, AKT/MAPK and COX-2/NF-κB signaling pathways. PLoS One, 9(5), 2014, e97799.
98. Fang, D., Hawke, D., Zheng, Y., Xia, Y., Meisenhelder, J., Nika, H., Mills, G.B., Kobayashi, R., Hunter, T., Lu, Z., Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity. J. Biol. Chem. 282:15 (2007), 11221–11229.
99. Huang, H.L., Hsieh, M.J., Chien, M.H., Chen, H.Y., Yang, S.F., Hsiao, P.C., Glabridin mediate caspases activation and induces apoptosis through JNK1/2 and p38 MAPK pathway in human promyelocytic leukemia cells. PLoS One, 9(6), 2014, e98943.
100. Liu, T., Wang, G., Tao, H., Yang, Z., Wang, Y., Meng, Z., Cao, R., Xiao, Y., Wang, X., Zhou, J., Capsaicin mediates caspases activation and induces apoptosis through P38 and JNK MAPK pathways in human renal carcinoma. BMC Cancer, 16(1), 2016, 790.
101. Matsuda, S., Kitagishi, Y., Peroxisome proliferator-activated receptor and vitamin d receptor signaling pathways in cancer cells. Cancers 5:4 (2013), 1261–1270.
102. Cannizzaro, L., Rossoni, G., Savi, F., Altomare, A., Marinello, C., Saethang, T., Carini, M., Payne, D.M., Pisitkun, T., Aldini, G., Leelahavanichkul, A., Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome. Nutr. Metab., 14(1), 2017, 5.
103. Lee, E.J., Kim, J.Y., Oh, S.H., Advanced glycation end products (AGEs) promote melanogenesis through receptor for AGEs. Sci. Rep., 6, 2016.
104. Rajasekar, P., Viswanathan, P., Anuradha, C.V., Renoprotective action of l-carnitine in fructose-induced metabolic syndrome. Diabetes Obes. Metab. 10:2 (2008), 171–180.
105. Iacobini, C., Menini, S., Ricci, C., Scipioni, A., Sansoni, V., Mazzitelli, G., Cordone, S., Pesce, C., Pugliese, F., Pricci, F., Pugliese, G., Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. J. Pathol. 218:3 (2009), 360–369.
106. Kannappan, S., Palanisamy, N., Anuradha, C.V., Suppression of hepatic oxidative events and regulation of eNOS expression in the liver by naringenin in fructose-administered rats. Eur. J. Pharmacol. 645:1 (2010), 177–184.
107. Brownlee, M.D.M., Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46:1 (1995), 223–234.
108. Thornalley, P.J., Cell activation by glycated proteins AGE receptors, receptor recognition factors and functional classification of AGEs. Cell. Mol. Biol. (Noisy-le-Grand, France) 44:7 (1998), 1013–1023.
109. Singh, R., Barden, A., Mori, T., Beilin, L., Advanced glycation end-products: a review. Diabetologia 44:2 (2001), 129–146.
110. Tesarova, P., Kalousova, M., Jachymova, M., Mestek, O., Petruzelka, L., Receptor for advanced glycation end products (RAGE)–soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 25 (2007), 720–725.
111. Jing, R., Wang, H., Jiang, S., Zhang, Z., Up-regulation of the receptor for advanced glycation end product (RAGE) in esophageal cancer and down-regulation in lung cancer and their relationship to clinicopathological features. Lab. Med. 39:11 (2008), 661–667.
112. Hirokikuniyasu, Y.C., Takahashi, T., Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 10 (2003), 445–448.
113. Sasahira, T., Kirita, T., Bhawal, U.K., Yamamoto, K., Ohmori, H., Fujii, K., Kuniyasu, H., Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 51:2 (2007), 166–172.
114. Bartling, B., Hofmann, H.S., Weigle, B., Silber, R.E., Simm, A., Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26:2 (2005), 293–301.
115. Lizotte, P.P., Hanford, L.E., Enghild, J.J., Nozik-Grayck, E., Giles, B.L., Oury, T.M., Developmental expression of the receptor for advanced glycation end-products (RAGE) and its response to hyperoxia in the neonatal rat lung. BMC Dev. Biol., 7, 2007, 15.
116. Sterenczak, K.A., Willenbrock, S., Barann, M., Klemke, M., Soller, J.T., Eberle, N., Nolte, I., Bullerdiek, J., Escobar, H.M., Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 434:1 (2009), 35–42.
117. Jiao, L., Taylor, P.R., Weinstein, S.J., Graubard, B.I., Virtamo, J., Albanes, D., Stolzenberg-Solomon, R.Z., Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol. Prev. Biomarkers 20:7 (2011), 1430–1438.
118. Huttunen, H.J., Rauvala, H., Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 255:3 (2004), 351–366.
119. Roth, J., Vogl, T., Sorg, C., Sunderkötter, C., Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol. 24:4 (2003), 155–158.
120. Riuzzi, F., Sorci, G., Donato, R., The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J. Biol. Chem. 281:12 (2006), 8242–8253.
121. Tabrez, S., Al-Shali, K.Z., Ahmad, S., Lycopene powers the inhibition of glycation-induced diabetic nephropathy: a novel approach to halt the AGE-RAGE axis menace. Biofactors 41:5 (2015), 372–381.
122. Ahmad, S., Immunogenicity of DNA damage by free radicals and carbonyls: a probable bio-marker for the auto-immune diseases. J. Immun. Res., 1(2), 2014, 2.
123. Akhter, F., Khan, M.S., Alatar, A.A., Faisal, M., Ahmad, S., Antigenic role of the adaptive immune response to d-ribose glycated LDL in diabetes, atherosclerosis and diabetes atherosclerotic patients. Life Sci. 151 (2016), 139–146.
124. Gopal, P., Rutten, E., Dentener, M.A., Wouters, E.F., Reynaert, N.L., Decreased plasma sRAGE levels in COPD: influence of oxygen therapy. Eur. J. Clin. Invest. 42:8 (2012), 807–814.
125. Taguchi, A., Blood, D.C., del Toro, G., Canet, A., Lee, D.C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., Hofmann, M.A., Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases. Nature 405:6784 (2000), 354–360.
126. Yamagishi, S., Nakamura, K., Inoue, H., Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med. Hypotheses 65:6 (2005), 1013–1015.
127. Cai, W., He, J.C., Zhu, L., Lu, C., Vlassara, H., Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc. Natl. Acad. Sci. 103:37 (2006), 13801–13806.
128. Yonekura, H., Yamamoto, Y., Sakurai, S., Petrova, R.G., Abedin, M.J., Hui, L.I., Yasui, K., Takeuchi, M., Makita, Z., Takasawa, S., Okamoto, H., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J 370:3 (2003), 1097–1109.
129. Challier, M., Jacqueminet, S., Benabdesselam, O., Grimaldi, A., Beaudeux, J.L., Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin. Chem. 51:9 (2005), 1749–1750.
130. Nakamura, K., Yamagishi, S.I., Adachi, H., Kurita‐Nakamura, Y., Matsui, T., Yoshida, T., Sato, A., Imaizumi, T., Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab. Res. Rev. 23:5 (2007), 368–371.
131. Tan, K.C., Shiu, S.W., Chow, W.S., Leng, L., Bucala, R., Betteridge, D.J., Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49:11 (2006), 2756–2762.
132. Nakamura, K., Yamagishi, S.I., Matsui, T., Adachi, H., Takeuchi, M., Imaizumi, T., Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin. Exp. Med. 7:4 (2007), 188–190.
133. Yamagishi, S.I., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Takeuchi, M., Enomoto, M., Furuki, K., Hino, A., Shigeto, Y., Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55:9 (2006), 1227–1231.
134. Nakamura, K., Yamagishi, S.I., Adachi, H., Kurita-Nakamura, Y., Matsui, T., Yoshida, T., Imaizumi, T., Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol. Med.-Cambridge MA Then New York, 13(3/4), 2007, 185.
135. Nakamura, K., Yamagishi, S.I., Adachi, H., Matsui, T., Kurita‐Nakamura, Y., Takeuchi, M., Inoue, H., Imaizumi, T., Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein‐1 (MCP‐1) levels in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 24:2 (2008), 109–114.
136. Yamagishi, S.I., Imaizumi, T., Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler. Thromb. Vasc. Biol., 27(6), 2007, e32.
137. Yamagishi, S., Matsui, T., Nakamura, K., Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr. Drug Targets 8 (2007), 1138–1143.
138. Miura, J., Yamamoto, Y., Osawa, M., Watanabe, T., Yonekura, H., Uchigata, Y., Yamamoto, H., Iwamoto, Y., Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler. Thromb. Vasc. Biol. 27:1 (2007), 253–254.
139. Forbes, J.M., Thorpe, S.R., Thallas-Bonke, V., Pete, J., Thomas, M.C., Deemer, E.R., Bassal, S., El-Osta, A., Long, D.M., Panagiotopoulos, S., Jerums, G., Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16:8 (2005), 2363–2372.
140. Nakamura, K., Yamagishi, S.I., Nakamura, Y., Takenaka, K., Matsui, T., Jinnouchi, Y., Imaizumi, T., Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res. 70:3 (2005), 137–141.
141. Chavakis, T., Bierhaus, A., Nawroth, P.P., RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect. 6:13 (2004), 1219–1225.
142. Herwig, N., Belter, B., Pietzsch, J., Extracellular S100A4 affects endothelial cell integrity and stimulates transmigration of A375 melanoma cells. Biochem. Biophys. Res. Commun. 477:4 (2016), 963–969.
143. Jiao, L., Weinstein, S.J., Albanes, D., Taylor, P.R., Graubard, B.I., Virtamo, J., Stolzenberg-Solomon, R.Z., Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 71:10 (2011), 3582–3589.
144. Bao, J.M., He, M.Y., Liu, Y.W., Lu, Y.J., Hong, Y.Q., Luo, H.H., Ren, Z.L., Zhao, S.C., Jiang, Y., AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am. J. Cancer. Res., 5(5), 2015, 1741.
145. Hsia, T.C., Yin, M.C., Mong, M.C., Advanced glycation end-products enhance lung cancer cell invasion and migration. Int. J. Mol. Sci., 17(8), 2016, 1289.
146. Alikhani, M., MacLellan, C.M., Raptis, M., Vora, S., Trackman, P.C., Graves, D.T., Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am. J. Physiol.-Cell Physiol. 292:2 (2007), C850–6.
147. Fujioka, S., Niu, J., Schmidt, C., Sclabas, G.M., Peng, B., Uwagawa, T., Li, Z., Evans, D.B., Abbruzzese, J.L., Chiao, P.J., NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol. Cell. Biol. 24:Sep 17 (2004), 7806–7819.
148. Huang, J.S., Guh, J.Y., Chen, H.C., Hung, W.C., Lai, Y.H., Chuang, L.Y., Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell. Biochem. 81:1 (2001), 102–113.
149. Wautier, M.P., Chappey, O., Corda, S., Stern, D.M., Schmidt, A.M., Wautier, J.L., Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol.-Endocrinol. Metab. 280:5 (2001), E685–E694.
150. Wautier, M.P., Chappey, O., Corda, S., Stern, D.M., Schmidt, A.M., Wautier, J.L., Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol.-Endocrinol. Metab. 280:5 (2001), E685–E694.
151. Christian, B., Angelika, B., Stefan, H., Axel, B., Peter, P.N., Eike, M., Markus, A.W., Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care, 12, 2008, 201.
152. Tang, D., Kang, R., Zeh, H.J., Lotze, M.T., High-mobility group box 1 and cancer. Biochim. Biophys. Acta (BBA)-Gene Regul. Mech. 1799:1 (2010), 131–140.
153. Degryse, B., Bonaldi, T., Scaffidi, P., Müller, S., Resnati, M., Sanvito, F., Arrigoni, G., Bianchi, M.E., The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152:6 (2001), 1197–1206.
154. Man, L.L., Liu, F., Wang, Y.J., Song, H.H., Xu, H.B., Zhu, Z.W., Zhang, Q., Wang, Y.J., The HMGB1 signaling pathway activates the inflammatory response in Schwann cells. Neural Regener. Res., 10(10), 2015, 1706.
155. Grasso, D., Garcia, M.N., Iovanna, J.L., Autophagy in pancreatic cancer. Int. J. Cell Biol., 2012, 2012.
156. Lui, G., Wong, C.K., Ip, M., Chu, Y.J., Yung, I.M., Cheung, C.S., Zheng, L., Lam, J.S., Wong, K.T., Sin, W.W., Choi, K.W., HMGB1/RAGE signaling and pro-inflammatory cytokine responses in non-HIV adults with active pulmonary tuberculosis. PLoS One, 11(7), 2016, e0159132.
157. Shirasuna, K., Seno, K., Ohtsu, A., Shiratsuki, S., Ohkuchi, A., Suzuki, H., Matsubara, S., Nagayama, S., Iwata, H., Kuwayama, T., AGEs and HMGB1 increase inflammatory cytokine production from human placental cells, resulting in an enhancement of monocyte migration. Am. J. Reprod. Immunol. 75:5 (2016), 557–568.
158. Wang, G., Liu, L., Zhang, Y., Han, D., Lu, J., Xu, J., Xie, X., Wu, Y., Zhang, D., Ke, R., Li, S., Activation of PPAR(attenuates LPS-induced acute lung injury by inhibition of HMGB1-RAGE levels. Eur. J. Pharmacol. 726 (2014), 27–32.
159. Wautier, J.L., Zoukourian, C., Chappey, O., Wautier, M.P., Guillausseau, P.J., Cao, R., Hori, O., Stern, D., Schmidt, A.M., Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest., 97(1), 1996, 238.
160. Mercado-Pimentel, M.E., Onyeagucha, B.C., Li, Q., Pimentel, A.C., Jandova, J., Nelson, M.A., The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells. FEBS Lett. 589:18 (2015), 2388–2393.
161. Onyeagucha, B.C., Mercado-Pimentel, M.E., Hutchison, J., Flemington, E.K., Nelson, M.A., S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Exp. Cell Res. 319:13 (2013), 2081–2090.